141 related articles for article (PubMed ID: 25488854)
21. Introduction.
Dahlöf B; Ritz E
Acta Diabetol; 2005 Apr; 42 Suppl 1():S1-2. PubMed ID: 15868114
[No Abstract] [Full Text] [Related]
22. [Diabetic nephropathy].
Agardh CD
Nord Med; 1992; 107(8-9):215-6. PubMed ID: 1408727
[TBL] [Abstract][Full Text] [Related]
23. High cardiovascular risk in patients with Type 2 diabetic nephropathy: the predictive role of albuminuria and glomerular filtration rate. The NID-2 Prospective Cohort Study.
Sasso FC; Chiodini P; Carbonara O; De Nicola L; Conte G; Salvatore T; Nasti R; Marfella R; Gallo C; Signoriello S; Torella R; Minutolo R;
Nephrol Dial Transplant; 2012 Jun; 27(6):2269-74. PubMed ID: 22090446
[TBL] [Abstract][Full Text] [Related]
24. [Clinical studies on chronic diabetic nephropathy and recent data concerning prevention of risks of nephropathy and cardiovascular diseases].
Esnault V
Nephrol Ther; 2006 May; 2 Suppl 3():S193-6. PubMed ID: 17370850
[TBL] [Abstract][Full Text] [Related]
25. [Risk and prevention of diabetic nephropathy].
Ravera M; Re M; Deferrari G
G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
[TBL] [Abstract][Full Text] [Related]
26. SONAR: Do a New Design and Statistically Significant Results Translate to Reliability?
Walsh M
Clin J Am Soc Nephrol; 2020 Jun; 15(6):889-891. PubMed ID: 32019759
[No Abstract] [Full Text] [Related]
27. [Diabetes mellitus and cardiovascular risk].
Valdés F; Lorenzo D; Calviño X; Cao M; Fernández Rivera C; Pérez Fontán M
Nefrologia; 2001; 21 Suppl 3():52-7. PubMed ID: 11642208
[No Abstract] [Full Text] [Related]
28. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
de Zeeuw D
Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
[TBL] [Abstract][Full Text] [Related]
29. Blood pressure and cardiovascular complications in diabetic dialysis patients.
Gutiérrez Vilaplana JM
EDTNA ERCA J; 2004; 30(3):128-30. PubMed ID: 15715113
[TBL] [Abstract][Full Text] [Related]
30. Dual therapy of vildagliptin and telmisartan on diabetic nephropathy in experimentally induced type 2 diabetes mellitus rats.
Sharma AK; Kanawat DS; Mishra A; Dhakad PK; Sharma P; Srivastava V; Joshi S; Joshi M; Raikwar SK; Kurmi MK; Srinivasan BP
J Renin Angiotensin Aldosterone Syst; 2014 Dec; 15(4):410-8. PubMed ID: 23396552
[TBL] [Abstract][Full Text] [Related]
31. Treatment and impact of dyslipidemia in diabetic nephropathy.
Toyama T; Shimizu M; Furuichi K; Kaneko S; Wada T
Clin Exp Nephrol; 2014 Apr; 18(2):201-5. PubMed ID: 24198049
[TBL] [Abstract][Full Text] [Related]
32. [Control of arterial pressure in diabetic nephropathy].
Luño J; García de Vinuesa S
Nefrologia; 2001; 21(3):240-5. PubMed ID: 11471304
[No Abstract] [Full Text] [Related]
33. Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease.
Smeijer JD; Kohan DE; Webb DJ; Dhaun N; Heerspink HJL
Curr Opin Nephrol Hypertens; 2021 Jul; 30(4):456-465. PubMed ID: 33990507
[TBL] [Abstract][Full Text] [Related]
34. Diabetic retinopathy, nephropathy and neuropathy. Generalized vascular damage in insulin-dependent diabetic patients.
Jensen T; Deckert T
Horm Metab Res Suppl; 1992; 26():68-70. PubMed ID: 1490695
[TBL] [Abstract][Full Text] [Related]
35. Diabetic nephropathy: implications for renal and cardiovascular outcomes.
Folan LA; Tuttle KR
Minerva Med; 2004 Oct; 95(5):385-94. PubMed ID: 15467514
[TBL] [Abstract][Full Text] [Related]
36. [Pathophysiology of diabetic nephropathy: a literature review].
Meza Letelier CE; San Martín Ojeda CA; Ruiz Provoste JJ; Frugone Zaror CJ
Medwave; 2017 Jan; 17(1):e6839. PubMed ID: 28112712
[TBL] [Abstract][Full Text] [Related]
37. [Cardiovascular disorders and possibilities of their therapy in patients with type 2 diabetes mellitus and diabetic nephropathy].
Onuchin SG; Elsukova OS; Solov'ev OV; Onuchina EL
Klin Med (Mosk); 2010; 88(1):32-7. PubMed ID: 20369609
[TBL] [Abstract][Full Text] [Related]
38. Angiotensin II antagonists--therapeutic benefits spanning the cardiovascular disease continuum from hypertension to heart failure and diabetic nephropathy.
Ribeiro AB
Curr Med Res Opin; 2006 Jan; 22(1):1-16. PubMed ID: 16393425
[TBL] [Abstract][Full Text] [Related]
39. Renal and stroke protection in hypertensive patients at CV risk.
Cardiovasc J Afr; 2007; 18(5):337, 340. PubMed ID: 17985036
[No Abstract] [Full Text] [Related]
40. [Is microalbuminuria, an early marker of clinical nephropathy, also a cardiovascular risk factor?].
Raynaud E; Brun JF; Fédou C; Puech-Cathala AM; Pérez-Martin A; Orsetti A
Ann Biol Clin (Paris); 1998; 56(6):671-9. PubMed ID: 9853026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
